PDK3 and cancer: These findings not only provide the NAC1-PDK3 axis as a novel molecular pathway involved in regulating mitochondrial function and survival of hypoxic tumor cells, but also suggest the potential of targeting NAC1 for enhancing ROS production as an effective strategy to improve pro-oxidative therapy in human cancer such as elesclomol.